NCT03821870CompletedNot Applicable
Predictive Value of In-vitro Anti-cancer Therapy Sensitivity Testing on Tumoroids From Patients With Metastatic Pancreatic Cancer
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Vejle Hospital
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Predictive value of in-vitro testing
Study Overview
Brief Summary
It will be investigated whether it is possible to predict the effect or lack of effect of first-line treatment by analysing cancer cells from the individual patient receiving standard first line treatment. Also, the feasibility of selecting second-line therapy based on pre-treatment biopsies will be investigated.
Cells from pancreatic cancer will be grown in the laboratory to form small, circulating tumors and adjacent tissue, so called tumoroids. The tumoroids will then be exposed to different pre-specified anticancer drugs to hopefully reveal sensitivity or lack of sensitivity in the specific patient.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Non-resectable pancreatic cancer
- •Biopsy proven adenocarcinoma compatible with pancreatic origin (primary tumor or metastasis)
- •If only biopsy from metastasis can be obtained, the patient must have a previously resected or image proven tumor of the pancreas
- •Deemed non-resectable at a multidisciplinary conference
- •Candidate to standard systemic therapy, defined as one of
- •Gemcitabine monotherapy,
- •Gemcitabine and nab-paclitaxel combination,
- •Gemcitabine and capecitabine combination,
- •5-fluorouracil, oxaliplatin and irinotecan combination (FOLFIRINOX), or
- •New standard treatments approved by the multidisciplinary cancer group 'Danish Pancreatic Cancer Group' in the inclusion period.
- •Measurable disease according to RECIST 1.1
- •ECOG performance status 0-2
- •Age at least 18 years
- •Adequate bone marrow, liver and renal function allowing systemic chemotherapy
- •Absolute neutrophil count ≥1.5x10^9/l and thrombocytes ≥ 100x10^9/l
- •Bilirubin ≤ 3 x upper normal value and alanine aminotransferase ≤ 5 x upper normal value
- •Calculated or measured renal glomerular filtration rate at least 30 mL/min
- •Contraception for fertile women and for male patients with a fertile partner. Intrauterine device, vasectomy of a female subject's male partner or hormonal contraceptive are acceptable
- •Written and orally informed consent
Exclusion Criteria
- •Potentially resectable disease
- •Incapacity, frailty, disability, or comorbidity to a degree that according to the investigator is not compatible with participation in the protocol
- •Other active malignant disease requiring therapy
- •Other systemic anti-cancer therapy (palliative radiotherapy is allowed)
- •Pregnant (positive pregnancy test) or breast feeding women
Arms & Interventions
Standard treatment
Standard first line treatment
Intervention: Inditreat (Diagnostic Test)
Standard treatment
Standard first line treatment
Intervention: Experimental drug (Drug)
Outcomes
Primary Outcomes
Predictive value of in-vitro testing
Time Frame: 2 months
Predictive value is defined as the ability to correctly predict response or resistance to first-line chemotherapy
Secondary Outcomes
- Feasibility of selecting second-line therapy based on pre-treatment biopsies as measured by treatment response (RESIST 1.1 criteria)(Every 2 months during treatment up to 180 days)
- Feasibility of selecting second-line therapy based on pre-treatment biopsies as measured by progression free survival (PFS)(Every 2 months up to 12 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal CancerColorectal Cancer MetastaticNCT03251612Vejle Hospital90
Active, not recruiting
Phase 1
Predictive value of analyzing cancer cells from patients with pancreatic cancer for possible effect of different anti-cancer drugsMedDRA version: 20.0 Level: LLT Classification code 10033605 Term: Pancreatic cancer metastatic System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10033606 Term: Pancreatic cancer non-resectable System Organ Class: 100000004864EUCTR2018-003112-53-DKVejle Hospital30
Active, not recruiting
Phase 1
Predictive value of testing the sensitivity of anticancer treatment on tumorspheres from patients with metastatic colorectal cancerMedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2017-000456-26-DKVejle Hospital90
Recruiting
Phase 2
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal TumorsImmunotherapyRectal CancerChemotherapy EffectRadiotherapyGastric CancerNCT05515796Daping Hospital and the Research Institute of Surgery of the Third Military Medical University200
Completed
Phase 1
Biodistribution and Dosimetry of 99mTc-DuramycinHealthy VolunteersNCT05177640University Hospital, Antwerp6